---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-047206"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:48:43.523870+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Palvella Therapeutics reports FY2024 net loss $17.4M, cash $83.6M; SELVA top-line Q1 2026 on track

## Summary
- Net loss $17.4M ($7.83/share) vs net income $17.9M in FY2023; R&D expense $8.2M, G&A $5.9M.
- Cash and equivalents $83.6M, expected to fund operations into H2 2027.
- Completed merger and $78.9M private placement in Dec 2024 with BVF, Frazier Life Sciences.
- Phase 3 SELVA top-line Q1 2026; Phase 2 TOIVA top-line Q4 2025; both for QTORIN rapamycin.
- Plans to expand QTORIN pipeline with new indication and product candidate in H2 2025.

## SEC filing metadata
- accession: 0000950170-25-047206
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000095017025047206/0000950170-25-047206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000095017025047206/pvla-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-047206
- JSON: https://secwatch.observer/filing/0000950170-25-047206.json
- Plain text: https://secwatch.observer/filing/0000950170-25-047206.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.